Valuation: Ocular Therapeutix, Inc.

Market Cap 1.96B 1.72B 1.58B 1.46B 2.75B 189B 2.81B 18.93B 7.45B 92.63B 7.38B 7.21B 319B P/E 2026 *
-5.6x
P/E 2027 * -6.37x
Enterprise Value 1.6B 1.4B 1.29B 1.19B 2.24B 154B 2.29B 15.43B 6.07B 75.51B 6.01B 5.88B 260B EV / Sales 2026 *
30.8x
EV / Sales 2027 * 16.2x
Free-Float
99.06%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ocular Therapeutix, Inc.

1 day-2.13%
1 week-12.06%
Current month-8.66%
1 month-4.88%
3 months-8.66%
6 months-20.41%
Current year-26.11%
1 week 8.81
Extreme 8.8101
10.18
1 month 8.81
Extreme 8.8101
10.94
Current year 6.23
Extreme 6.2301
13.03
1 year 6.23
Extreme 6.2301
16.44
3 years 2
Extreme 1.995
16.44
5 years 2
Extreme 1.995
16.44
10 years 2
Extreme 1.995
24.3
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2024
Director of Finance/CFO 50 20/01/2026
Chief Tech/Sci/R&D Officer 49 20/05/2024
Director TitleAgeSince
Chairman 57 01/07/2019
Director/Board Member 78 05/11/2012
Director/Board Member 66 20/03/2019
Date Insider Type Main position Quantity % Market Cap.
16/06/26 Don

Chief Executive Officer

-100,184 0.0473%
10/06/26 Free

Executive/Senior Manager

29,465 0.0139%
10/06/26 Free

Director

58,000 0.0274%
Change 5-day change 1-year change 3-year change Capi.($)
-2.13%-12.06%-20.83%+99.78% 1.96B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.28%-0.72%+23.60%+58.50% 357.7B
Weighted average by Cap. +0.37%+0.02%+37.48%+79.64%

Financials

2026 *2027 *
Net sales 51.91M 45.36M 41.86M 38.58M 72.72M 5B 74.34M 500M 197M 2.45B 195M 191M 8.43B 120M 105M 97.05M 89.46M 169M 11.59B 172M 1.16B 456M 5.68B 452M 442M 19.54B
Net income -362M -316M -292M -269M -507M -34.84B -518M -3.49B -1.37B -17.06B -1.36B -1.33B -58.73B -331M -289M -267M -246M -463M -31.84B -473M -3.19B -1.25B -15.59B -1.24B -1.21B -53.68B
Net Debt -363M -317M -293M -270M -509M -34.96B -520M -3.5B -1.38B -17.12B -1.36B -1.33B -58.94B -18M -15.73M -14.52M -13.38M -25.22M -1.73B -25.78M -173M -68.24M -849M -67.6M -66.12M -2.92B
Logo Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company. AXPAXLI, also known as OTX-TKI, the Company's investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel-based formulation technology. Its pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA, a corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate PAXTRAVA, which is a travoprost intracameral hydrogel for the treatment of open-angle glaucoma or ocular hypertension. The ELUTYX technology provides delivery solutions for durable therapies for wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other diseases.
Employees
325
Date Price Change Volume
17/07/26 $8.970 -2.13% 1,880,853
16/07/26 $9.165 -7.98% 2,719,495
15/07/26 $9.960 +2.68% 1,322,841
14/07/26 $9.700 -1.82% 1,427,317
13/07/26 $9.880 -3.14% 1,437,618
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.970USD
Average target price
27.09USD
Spread / Average Target
+202.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OCUL Stock